Testicular mesothelioma (TM), especially mesothelioma of the tunica vaginalis testis (TVT), is an uncommon variant of mesothelioma, a cancer developing from the mesothelial cells that cover serous membranes. Protheragen focuses on TM diagnostics and therapeutics development, providing tailored services and streamlining workflows to meet TM project requirements. Our tailored services include histological and immunohistochemical analysis, molecular diagnostics, and preclinical research.
Overview of Testicular Mesothelioma (TM)
Testicular mesothelioma (TM) is a remarkably uncommon form of mesothelioma that develops from the mesothelial tissue that covers the testis. It is one of the rarest tumors in oncology, comprising under 1% of all mesothelioma cases. The signs and symptoms of TM usually include scrotal pain, swelling, or discomfort, and are often seen in patients with a prior history of asbestos exposure. The time lag between asbestos exposure and TM development is between 24 and 72 years, demonstrating the long-term cancer-promoting impact of asbestos fibers.
Fig.1 Histologic and immunohistochemical features of malignant mesothelioma of the tunica vaginalis testis. (Hocking A. J.,
et al., 2023)
Pathogenesis of Testicular Mesothelioma (TM)
Both genetic and environmental components influence the pathogenesis of testicular mesothelioma. The most common and well-known cause of this condition is asbestos exposure, which has a latency period of a little over 25 years. The genetic aspects are, however, a lot more intertwined. Asbestos fibers cause necrosis of mesothelial cells due to DNA damage, and the liberating DAMPs of necrosis (enhanced HMGB1) will prompt the damaged cells to proliferate, which is the basis for the damage-asbestos-induced carcinogenesis. Also, there are genetic changes added to the scenario, such as mutations in the tumor suppressor genes NF2 and TP53, which are quite common in TM.
Diagnostics Development for Testicular Mesothelioma (TM)
- Histological and Immunohistochemical Analysis
For a TM diagnosis, a histological examination together with TM-specific immunohistochemical staining is essential. Mesothelial immunohistochemical markers calretinin, CK5/6, AE1/3, WT1, D2-40 are positive while carcinoma markers CEA, TTF-1, BerEp4, PAX8, CDX2, PSA and BG8 are negative. With this assorted combination of markers, TM can be differentiated from other malignancies.
- Molecular Diagnostics
In the TM cases, whole-exome and whole-genome sequencing have been utilized to detect molecular alterations. These methods disclose alterations in the NF2 and TP53 genes, which are frequently altered in mesothelioma of the pleura and peritoneum. Molecular diagnostics enhance the understanding of the genetics of TM, which is helpful in the formulation of precisely allocated therapeutic strategies.
Therapeutics Development for Testicular Mesothelioma (TM)
- Immunotherapy: Immunotherapy has been checkpoint inhibitors therapy with nivolumab and ipilimumab, which has been useful in treating mesothelioma. These drugs work by stimulating the body's immune system to combat cancer more effectively. The combination therapy with nivolumab and ipilimumab has shown a median overall survival of 15.9 months in clinical trials.
- Targeted Therapy: Research is being conducted into targeted therapies TM TM-specific therapies based on certain genetic alterations. For instance, therapies based on NF2 or TP53 mutations may one day be possible. These specific strategies seek to alter the TM pathogenesis at specific, defined, and crucial points.
- CAR-T Cell Therapy: Chimeric Antigen Receptor (CAR) T-cell Therapy is a new therapeutic for TM. CAR-T Cells are devised to fight against tumor cells that express certain antigens like mesothelin. Clinical studies are in progress to assess the efficacy and safety of CAR-T Cell Therapy in TM.
Table 1. Overview of preclinical studies of genetic therapy in mesothelioma. (Štrbac D., et al., 2022)
| Used Therapeutic Agent |
Endpoints of the Study |
Major Findings |
Type of Study |
| Pladienolide-B, E7107, Meayamycin-B |
To investigate whether splicing modulators are capable of modifying the cell cycle and apoptosis. |
Splicing modulators compromise the viability of mesothelioma cancer cells. |
Preclinical, mesothelioma cell lines |
| miR-15/16 |
To investigate the suppression of fibroblast growth factor (FGF) expression mediated by miR-15/16. |
miR-15/16 can downregulate FGF and inhibit the growth of mesothelioma cells. |
Preclinical, mesothelioma cell lines |
| DFP-10825 (shRNA) |
To explore whether cationic liposomes carrying shRNA targeting thymidylate synthase can suppress cell proliferation in peritoneal mesothelioma. |
High therapeutic effect without severe side effects. |
Preclinical, mouse model |
| miR-137 |
To investigate whether the Y box binding protein 1 gene (YBX1) is capable of reducing miR-137 levels in mesothelioma. |
The combination of miR-137 and YBX1 can inhibit the proliferation, invasion, and migration of mesothelioma cells. |
Preclinical, mesothelioma cell lines |
| miR-126 |
To investigate whether the restoration of miR-126 expression can suppress cell invasion and proliferation. |
MiR-126 induces G1/S cell cycle arrest and inhibits proliferation. |
Preclinical, mesothelioma cell lines |
| miR-182/miR-183 |
To examine whether suppressing miR-182/miR-183 can attenuate the proliferation and migration capabilities of mesothelioma cells. |
miR-182/miR-183 inhibitors can reduce the proliferation and migration of mesothelioma cells. |
Preclinical, mesothelioma cell lines |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers comprehensive diagnostics and therapeutics development services for testicular mesothelioma (TM). Our services encompass histological and immunohistochemical analysis, molecular diagnostics, and advanced imaging techniques to facilitate accurate diagnosis. We also provide preclinical research services, including the development of metastatic tumor models, to support the evaluation of novel therapeutic approaches.
Disease Models
- Primary Cell Cultures
- Human / Rat / Porcine Testicular Organoids
- Patient-Derived Xenograft (PDX) Models
- Erionite-Induced Mesothelioma Models
- Genetically Engineered Models (GEMs)
Protheragen's preclinical research services for TM include the development of metastatic tumor models, which are essential for evaluating the efficacy of new therapeutics. Our models are designed to mimic the clinical presentation and progression of TM, providing a robust platform for testing novel therapies. If you are interested in our services, please feel free to contact us.
References
- Hocking, Ashleigh Jean, et al. "Molecular characterization of testicular mesothelioma and the role of asbestos as a causative factor." Archives of pathology & laboratory medicine 147.12 (2023): 1446-1450.
- Štrbac, Danijela, and Vita Dolžan. "Novel and future treatment options in mesothelioma: a systematic review." International journal of molecular sciences 23.4 (2022): 1975.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
